Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881404 | 1.00 | NFE2L2 (0.60) | NFE2L2HCAR2KEAP1CA12CA1 | |
| SCHEMBL17268283 | 0.83 | NFE2L2 (0.52) | NFE2L2HCAR2KEAP1CA12CA1 | |
| SCHEMBL13422419 | 0.83 | NFE2L2 (0.52) | NFE2L2HCAR2KEAP1CA12CA1 | |
| SCHEMBL24425888 | 0.78 | NFE2L2 (0.52) | NFE2L2HCAR2KEAP1CA12CA1 | |
| SCHEMBL18929987 | 0.78 | NFE2L2 (0.52) | NFE2L2HCAR2KEAP1CA12CA1 | |
| SCHEMBL18960907 | 0.77 | KEAP1 (0.32) | NFE2L2HCAR2KEAP1 | |
| SCHEMBL321328 | 0.77 | NFE2L2 (0.57) | NFE2L2HCAR2KEAP1CA12CA1 | |
| SCHEMBL1880638 | 0.77 | DGAT1 (0.34) | NFE2L2HCAR2KEAP1DGAT1 | |
| SCHEMBL2418087 | 0.77 | NFE2L2 (0.57) | NFE2L2HCAR2KEAP1CA12CA1 | |
| SCHEMBL14457285 | 0.77 | KEAP1 (0.32) | NFE2L2HCAR2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-9145392-B2 | Imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-29 | — | — | US | disclosed |
| US-9145392-B2 | Imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-29 | — | — | US | disclosed |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8354540-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-7501408-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080293674-A1 | Azinyl Imidazoazine and Azinyl Carboxamide | BAYER CROPSCIENCE AG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080167312-A1 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073863-A2 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7314872-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-01-01 | — | — | US | disclosed |
| EP-1658267-A4 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-08-01 | — | — | EP | disclosed |
| EP-1658267-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | disclosed |
| WO-2005034848-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293674-A1 | Azinyl Imidazoazine and Azinyl Carboxamide | AZI2, NISCH, ZYX | NFE2L2 1637/4885HCAR2 758/4885KEAP1 3107/4885 |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | NFE2L2 1902/4885HCAR2 128/4885KEAP1 945/4885 |
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | NFE2L2 1207/4885HCAR2 2273/4885KEAP1 1429/4885 |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | NFE2L2 375/4885HCAR2 57/4885KEAP1 497/4885 |
| US-20080167312-A1 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | UGT1A7, UGT2B7, UGT1A10 | NFE2L2 1258/4885HCAR2 4353/4885KEAP1 491/4885 |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | NFE2L2 1207/4885HCAR2 2273/4885KEAP1 1429/4885 |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | NFE2L2 3420/4885HCAR2 2625/4885KEAP1 2818/4885 |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | AR, LHCGR, FSHR | NFE2L2 2490/4885HCAR2 136/4885KEAP1 2974/4885 |
| US-20050113356-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | NFE2L2 3420/4885HCAR2 2625/4885KEAP1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.